Kamil Musilek

Hradec Kralove, KR 50003, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 155 publications

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

Discovery of 1-(3-phenoxybenzyl)-4-(1-phenyl-1H-1,2,3-triazol-4-yl)piperidine analogues as potent and selective agonists of the human CC chemokine receptor 8.

Discovery of 1-(3-phenoxybenzyl)-4-(1-phenyl-1H-1,2,3-triazol-4-yl)piperidine analogues as potent and selective agonists of the human CC chemokine receptor 8.

Journal: European journal of medicinal chemistry

Published: April 28, 2026

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents.

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget-Directed Anti-Alzheimer Agents.

Journal: Drug development research

Published: March 23, 2026

Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.

Development of Novel 17β-HSD10 Inhibitors and Their Evaluation in an In Vitro Model of Alzheimer's Disease.

Journal: ACS medicinal chemistry letters

Published: March 09, 2026

Reactivation screening of A-234-inhibited human recombinant acetylcholinesterase in vitro.

Reactivation screening of A-234-inhibited human recombinant acetylcholinesterase in vitro.

Journal: Chemico-biological interactions

Published: August 28, 2025

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 08, 2025

Transforming ureas into carbamates: From allosteric p38α MAPK ligands to dual BChE/p38α MAPK inhibitors.

Transforming ureas into carbamates: From allosteric p38α MAPK ligands to dual BChE/p38α MAPK inhibitors.

Journal: Bioorganic chemistry

Published: July 14, 2025

Combination of oximes as experimental therapeutic approach to organophosphates poisonings: a critical review.

Combination of oximes as experimental therapeutic approach to organophosphates poisonings: a critical review.

Journal: Chemico-biological interactions

Published: July 02, 2025

Small-Molecule Kinase Inhibitors Modulating Circadian Rhythms.

Small-Molecule Kinase Inhibitors Modulating Circadian Rhythms.

Journal: Medicinal research reviews

Published: June 10, 2025

New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease.

New insights into the 17β-hydroxysteroid dehydrogenase type 10 and amyloid-β 42 derived cytotoxicity relevant to Alzheimer's disease.

Journal: Alzheimer's research & therapy

Published: April 22, 2025

Non-oxime reactivators of organophosphate-inhibited cholinesterases.

Non-oxime reactivators of organophosphate-inhibited cholinesterases.

Journal: Archives of toxicology

Published: April 14, 2025

Interplay between circadian rhythms and epigenetics in neural stem cells and Alzheimer's disease.

Interplay between circadian rhythms and epigenetics in neural stem cells and Alzheimer's disease.

Journal: Progress in neurobiology

Published: April 10, 2025

Showing 1-12 of 155

Last Updated: 09/26/2026